NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
BioSpace
Mon, 06/24/24 - 11:24 am
NeuroBo Pharmaceuticals
DA-1726
ADA
weight loss
FDA approves NeuroBo’s DA-1726 application to begin Phase I trial
Clinical Trials Arena
Fri, 02/2/24 - 11:55 am
NeuroBo Pharmaceuticals
DA-1726
FDA
clinical trials
obesity
NeuroBo to begin clinical trial of NB-01 in adult patients with diabetic neuropathic pain
Pharmaceutical Business Review
Wed, 01/9/19 - 01:39 pm
NeuroBo Pharmaceuticals
NB-01
diabetic neuropathy
clinical trials